Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences

BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in five upcoming investor conferences:

• Praxis management will be presenting a corporate overview at the 45^th Annual TD Cowen Health Care Conference, taking place at the Boston Marriott Copley Place in Boston on Wednesday, March 5, 2025 at 9:10a.m. EDT. A live webcast of the event will be available through this .
• Praxis management will also be participating in a fireside chat at the Leerink Partners Global Healthcare Conference, taking place at the W South Beach Hotel in Miami on Monday, March 10, 2025 at 3:40p.m. EDT. A live webcast of the event will be available through this .
• Praxis management will also be participating in one-on-one investor meetings at the Jefferies Biotech on the Bay Summit, taking place at the Ritz Carlton South Beach Hotel in Miami on Tuesday, March 11, 2025.
• Praxis management will also be participating in a fireside chat at the Barclays 27^th Annual Global Healthcare Conference, taking place at the Loews Miami South Beach Hotel in Miami on Wednesday, March 12, 2025 at 2:30p.m. EDT. A live webcast of the event will be available through this .
• Praxis management will also be participating in a fireside chat at the UBS Virtual CNS Day, taking place on March 17, 2025 at 9:30a.m. EDT. A live webcast of the event will be available through this .
  
  

The Company will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.

Replays of the webcasted events will also be available through the “” page under the “” section of the company’s website for 90 days.

About Praxis  

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit and follow us on , and .